Account
Articles
21.06.2023
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more
Insider Insights
13.06.2023
Collaboration proposes a new method for combinatio...

In a joint report Lif, the New Therapeutics (NT) Council and representatives of the regions have pro...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
Newsletter
07.06.2023
PMA Insights: Week 23

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Newsletter
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Case Study
01.01.2023
Developing scenario-based commercial assessments

Identification of current cost of oncology care treatment options.

Read more
Publications
28.09.2022
ISPOR 2022: Does NICE’S STA Process Effectively ...

We investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...

Read more
Insider Insights
27.07.2022
Macmillan alliance will provide digital health app

According to Big health, randomised controlled trials have shown that 71% of patients who used Dayli...

Read more
Insider Insights
27.05.2022
New coalition to improve access to cancer drugs in

According to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.